N 6 -methyladenosine (m 6 A) is an essential RNA modification that regulates key cellular processes, including stem cell renewal, cellular differentiation, and response to DNA damage. Unsurprisingly, aberrant m 6 A methylation has been implicated in the development and maintenance of diverse human cancers. Altered m 6 A levels affect RNA processing, mRNA degradation, and translation of mRNAs into proteins, thereby disrupting gene expression regulation and promoting tumorigenesis. Recent studies have reported that the abnormal expression of m 6 A regulatory enzymes affects m 6 A abundance and consequently dysregulates the expression of tumor suppressor genes and oncogenes, including MYC, SOCS2, ADAM19, and PTEN. In this review, we discuss the specific roles of m 6 A "writers", "erasers", and "readers" in normal physiology and how their altered expression promotes tumorigenesis. We also describe the potential of exploiting the aberrant expression of these enzymes for cancer diagnosis, prognosis, and the development of novel therapies.
Introduction
RNA modifications have recently been shown to play important roles in normal and disease biology. Over 170 different types of post-transcriptional modifications have been identified in RNA, many of which have unknown functions. Among all RNA modifications, N 6 -methyladenosine (m 6 A) is the most abundant internal modification on eukaryotic mRNAs. m 6 A occurs predominantly at the consensus RRACH motif and is enriched near the 5' or 3' untranslated regions (UTRs) of mRNAs 1, 2 . m 6 A is now established as a key modification that influences virtually all aspects of mRNA fate and metabolism, including mRNA stability 3, 4 , splicing 1, 3, 5 , transport and localization 4 , translation [6] [7] [8] , microRNA (miRNA) processing 9 , and RNA-protein interactions 10 . Advances in characterizing m 6 A were made possible through the recent development of m 6 A immunoprecipitation and sequencing techniques 1, 2 and the discovery of enzymes that regulate m 6 A modification 4, [11] [12] [13] [14] . Enzymes that regulate m 6 A deposition on mRNAs and their consequent transcriptional outcomes include RNA specific methylases (writers), demethylases (erasers), and reader proteins (Figure 1) .
Together, the tightly-regulated functions of m 6 A writers, erasers, and readers are critical in maintaining the integrity of m 6 A RNA modification in cells. Recent studies have indicated that the aberrant expression of these enzymes is involved in human diseases, including cancer. In this review, we describe the roles of known writers, erasers, and readers of m 6 A mRNA methylation in diverse biological processes. We summarize the role of the overexpression and/or downregulation of m 6 A regulatory enzymes in promoting cancer initiation and progression ( Figure 2 , Table 1 ). We also discuss the potential of targeting m 6 A regulatory enzymes with aberrant expression for cancer therapy.
interactions with its target mRNAs 15 . WTAP ensures the localization of the METTL3/METTL14 heterodimer to nuclear speckles where m 6 A RNA methylation occurs 16 .
Ancillary to this METTL3/METTL14/WTAP core machinery are several m 6 A regulatory proteins necessary for the full methylation program, including virilizer like m 6 A methyltransferase associated protein (VIRMA), zinc-finger CCCH-type containing 13 (ZC3H13), Cb1 proto-oncogene like 1 (CBLL1), and RNA-binding motif protein 15 (RBM15) 7, 13, 14, 17, 18 . Knockdown of each of these proteins leads to a significant decrease in m 6 A deposition 7, 13, 14 . In addition, VIRMA was recently shown to mediate the recruitment of the methyltransferase core subunits to the 3' UTRs and stop codons for region-selective RNA methylation 17 . Depletion of VIRMA was shown to result in the lengthening of the 3' UTR in hundreds of mRNAs with significant overlap in target transcripts 17 . As a large 202 kD protein, VIRMA has also been proposed to be a scaffold upon which all other subunits attach. RBM15, an RNA structure recognizing protein, is involved in complex recruitment to specific consensus sequences for m 6 A methylation 7 . This protein interacts with WTAP via ZC3H13 18 . ZC3H13 also regulates the nuclear localization of the complex that comprises WTAP, VIRMA, and CBLL1 14 . Upon ZC3H13 depletion, methyltransferase complexes form in the cytoplasm, which may be counterproductive for m 6 'writers' including METTL3, METTL14, WTAP, ZC3H13, CBLL1, VIRMA and RBM15, localizes to the nuclear speckles where it methylates target RNA transcripts. Conversely, FTO and ALKBH5 (m 6 A 'erasers') remove m 6 A from select transcripts, establishing a dynamic equilibrium between methylated and unmethylated RNA transcripts within the cell. Finally, proteins like YTHDF1-3, YTHDC1, IGF2BPs and eIF3 (m 6 A 'readers') recognize and bind m 6 A to direct essential molecular functions such as RNA splicing, nuclear export, translation and RNA decay. methylation because it occurs primarily in the nucleus 14 . Other proteins, including TRIM28 and HNRNPH, have also been identified as components of the m 6 A methyltransferase complex although their specific roles remain unclear 17 . Coimmunoprecipitation studies using different antibodies have identified 26 core interacting factors among hundreds of WTAP-binding proteins, while more than 100 proteins may bind METTL3 or METTL14 19, 20 . Thus, there may be other components of the m 6 A methyltransferase complex that have not yet been identified.
m 6 A mRNA methylation is removed via specific demethylases
Unlike the large multi-subunit m 6 A methyltransferase complex, only two m 6 A demethylases have been identified: the fat-mass and obesity-associated protein (FTO) and AlkB homolog 5 (ALKBH5) 4, 11 . Both FTO and ALKBH5 are members of the AlkB family of Fe(II)/α-ketoglutaratedependent dioxygenases with a well-conserved catalytic domain. The knockdown and overexpression of both enzymes have been shown to affect functions regulated by m 6 A methylation, including splicing, RNA stability, and translation 3, 21, 22 . While the function of each of these enzymes is to remove m 6 A, they also appear to act on select subsets of mRNA targets, which is consistent with their enrichment in different tissues and subcellular compartments 4, 23 . A recent study demonstrated that target recognition by FTO and ALKBH5 is not dependent on the consensus m 6 A sequence motif but instead the structure and conformation of target P r o s ta te c a n c e r P a n c r e a ti c c a n c e r m 6 A IG F 2 B P s C e r v ic a l c a n c e r L iv e r c a n c e r 24 . However, mRNA targets of FTO and ALKBH5 cannot be distinguished by RNA structure and conformation alone 24 . The specificity of mRNA substrate recognition by these enzymes remains to be determined. m 6 A mRNA methylation is recognized by reader proteins to confer specific phenotypic outcomes
Writers
The most well-studied readers of m 6 A are the YT521-B homology (YTH) family of proteins. Structurally, this family of proteins shares a 100-150 amino acid residue YTH domain, forming a hydrophobic aromatic cage to accommodate and recognize m 6 A modifications 25 . This cagelike structure has high selectivity for the N 6 -modified adenosine within the RRACH consensus motif. Of these proteins, YTHDF1-3 are cytoplasmic m 6 A readers that have a variety of functions. YTHDF1 has been implicated in ribosome loading for transcript translation, while YTHDF2 regulates mRNA stability and translation 26, 27 . In contrast, YTHDC1 is a nuclear m 6 A reader reported to assist in the localization of modified transcripts and the formation of focal sites of transcription called YT bodies adjacent to nuclear speckles 28 . YTHDC1 further interacts with several splicing factors, including SRSF3 and SRSF10, to regulate splicing 28 . The insulin-like growth factor-2 mRNA-binding proteins 1-3 (IGF2BP1-3) have also been reported to be m 6 A readers 29 . They possess K homology domains necessary for interaction with m 6 A-modified RNA. In contrast to YTHDF2, which destabilizes mRNA, IGF2BP1-3 proteins promote transcript stability by inhibiting degradation, enhancing storage, and facilitating translation of their target mRNAs 29 .
Expression of m 6 A writers is altered in diverse cancers

METTL3
The role of aberrant METTL3 expression in cancers is well characterized. In lung adenocarcinoma, METTL3 overexpression promotes growth, survival, and invasion of cancer cells 6 , whereas the repression of METTL3 expression in non-small cell lung cancer inhibits cell proliferation 30 . Increased expression of METTL3 enhances the translation of oncogenes, including EGFR, TAZ, MK2, and DNMT3, via interaction with the translation initiation complex 6 . Thus, besides introducing m 6 A in transcripts, METTL3 might also function as an m 6 A reader in the cytoplasm through interaction with the translation machinery 6 . Indeed, METTL3 has recently been shown to localize to the polyribosomes and interact directly with the eukaryotic translation initiation factor 3 subunit h (eIF3h) in lung cancer 31 . This interaction induces mRNA circularization, 31 . In breast adenocarcinoma, METTL3 expression is regulated by an oncoprotein, the hepatitis B X-interacting protein (HBXIP) 32 . HBXIP suppresses a miRNA, let-7g, which typically targets METTL3 32 . The consequent increase in METTL3 expression further enhances HBXIP expression via m 6 A modification of transcripts encoding this oncogene. This positive feedback loop involving HBXIP/let7g/METTL3/HBXIP drives the proliferation of breast cancer cells 32 .
METTL3 overexpression has been observed in hepatocellular carcinoma (HCC) and is associated with poorer survival 33 . Depletion of METTL3 reduces cell proliferation, migration, and colony formation in vitro and also decreases HCC tumorigenicity and metastasis capacity in vivo 33 . METTL3 directly targets the tumor suppressor gene SOCS2 to facilitate its degradation via an m 6 A-dependent YTHDF2-mediated mechanism 33 .
The association between METTL3 levels and glioblastoma development and maintenance remains unclear. One study showed that reduced METTL3 levels enhance glioblastoma stem-like cell (GSC) growth, self-renewal, and tumorigenesis 34 . Knockdown of METTL3 and METTL14 was shown to lead to the upregulation of oncogenes, including ADAM19, EPHA3, and KLF4 34 , and downregulation of a number of tumor suppressor genes such as CDKN2A, BRCA2, and TP53I11 34 . However, another study showed that METTL3 was overexpressed in GSCs and glioblastoma samples 35 . Importantly, elevated METTL3 levels are associated with poorer survival in patients with glioblastoma 35 . METTL3 depletion was found to reduce tumor growth and prolong survival in mice, indicating that a decrease in METTL3 is unfavorable for the maintenance of glioblastoma 35 . Despite these discrepancies, it is clear that the aberrant expression of METTL3 is involved in this type of brain cancer. It is likely that the expression of m 6 A RNA methylases needs to be maintained within an optimal range to prevent progression to cancer.
In acute myeloid leukemia (AML), METTL3 expression appears to be a key driver of leukemia maintenance. METTL3 was identified in two independent CRISPR screens as an essential oncogene, and it functions to suppress apoptosis and myeloid differentiation 36, 37 . Consistent with this finding, AML exhibited the highest levels of METTL3 expression among all cancers studied by The Cancer Genome Atlas Research Network (TCGA). Depletion of METTL3 in AML cell lines promotes cell differentiation and apoptosis and impairs leukemogenesis in murine leukemia models 36, 37 .
Mechanistically, METTL3 overexpression drives AML development and maintenance via two possible pathways. First, an increase in METTL3 levels promotes the m 6 A methylation-mediated translation of mRNAs encoding apoptosis repressors and/or oncogenes, including c-MYC, BCL2, and PTEN 36 . Second, METTL3 binds to the promoter of target genes via a CCAAT-box binding factor, in a CEBPZdependent mechanism, to promote their translation 37 . This process occurs as promoter-bound METTL3 potentiates the m 6 A methylation of transcripts encoded by these same genes to relieve ribosome stalling 37 . Promoters of key transcription factors, including SP1 and SP2, are among those bound by METTL3 37 . Importantly, SP1 is a known oncogene that regulates c-MYC expression 38 . Thus, when elevated, METTL3, directly or indirectly, targets mRNAs encoding oncogenic proteins to drive leukemogenesis.
METTL14
METTL14 plays a fundamental role in the recognition of RNA substrates for m 6 A methylation. Therefore, aberrant expression of METTL14 can alter the fate of transcripts regulated by m 6 A. METTL14 has been reported to alter m 6 A levels in HCC 39 . It regulates the miRNA biogenesis pathway by facilitating the binding of the microprocessor complex subunit DGCR8 to primary miRNA in an m 6 A-dependent manner 39 . One prominent example is miR-126, which suppresses metastasis in HCC and breast cancer 40, 41 . METTL14 overexpression increases the abundance of m 6 A methylation on primary miR-126, enhancing its recognition by DGCR8 for processing into mature miRNA 39 . Accordingly, depletion of METTL14 reduces the expression of mature miR-126, while overexpression of METTL14 accelerates miR-126 processing in HCC cells in vitro.
Clinically, low METTL14 expression was correlated with metastasis and poorer survival in one cohort of 130 patients with HCC 39 . In contrast, an independent study reported no change in METTL14 expression in the TCGA cohort of 50 HCC samples and showed that the stable repression of METTL14 suppresses proliferation, migration, and colony formation in vitro 33 . The discrepancy in the reports by these two groups suggests that METTL14 levels may need to fall within a certain range for normal functions in cells and that uncontrolled regulation, leading to sub-optimal expression, may promote tumorigenesis.
METTL14 is also expressed at high levels in hemopoietic stem and progenitor cells and is downregulated during myeloid cell differentiation 42 ; correspondingly, human AML cells bearing one of the abnormal chromosomal translocations t(11q23), t(15; 17), or t(8; 21) all overexpress METTL14 42 . The MYC and MYB oncogenes have been identified as METTL14 targets that are post-transcriptionally regulated in an m 6 A-dependent manner 42 . Thus, overexpression of METTL14 may promote leukemogenesis by enhancing the stability of transcripts encoding these oncogenes and their subsequent translation.
Up to 70% of endometrial cancers have been shown to exhibit reduced m 6 A levels, consistent with the presence of a METTL14 mutation and reduced expression of METTL3 43 . These aberrant changes promote cell proliferation. They are associated with decreased levels of a negative regulator of AKT, PHLPP2, and increased expression of mTORC2, which enhances AKT activity 43 . Thus, endometrial cancer may develop via altered m 6 A-modulated activity of the AKT signaling pathway 43 .
Other components of the m 6 A writer complex
Other subunits of the m 6 A writer complex have previously been implicated in tumorigenesis. WTAP is an oncogene in diverse cancers, including glioblastoma 44 , cholangiocarcinoma 45 , and AML 46 . Its overexpression is associated with poor prognosis in AML 46 , glioma 47 , and pancreatic ductal adenocarcinoma 48 . RBM15 was first identified as a fusion oncogene (RBM15-MKL1) involved in the recurrent translocation t(1; 22)(p13; q13) in infant acute megakaryoblastic leukemia 49 and less frequently in other subtypes of AML 50 . RBM15 mutations have also been implicated in the pathogenesis of phyllodes tumors 51 . Nevertheless, the exact molecular mechanisms responsible for the oncogenic properties of WTAP and RBM15 overexpression remain elusive. Whether their aberrant expression leads to downstream disruption of target oncogenes and/or tumor suppressor genes via altered m 6 A abundance remains to be determined.
Aberrant expression of m 6 A erasers promotes tumorigenesis FTO
Aberrant expression of FTO has been shown to be favorable for the survival and expansion of diverse cancer cells. The overexpression of FTO has been reported in subsets of AML bearing mixed lineage leukemia rearrangements, t(15; 17) translocation, FLT3-ITD, and/or NPM1 mutations 21 . Notably, induced overexpression of FTO promotes the survival, proliferation, and transformation of AML cells in vitro and in vivo 21 . Reduced m 6 A abundance has been observed in the 3' UTR of mRNA targets, including ASB2 and RARA, consequent to FTO overexpression in AML cell lines 21 . This effect is consistent with increased m 6 A demethylase activity, thereby decreasing the stability of these transcripts encoding myeloid differentiation factors. This aberration blocks myeloid differentiation, which is a hallmark of AML.
However, the consequences of FTO expression in AML are complex when considered in relation to the mutational status of the α-ketoglutarate-dependent dioxygenases IDH1/2 52 . IDH1/2 mutations occur in approximately 20% of AML cases and produce a structurally related metabolite, D-2-hydroxyglutarate, that competitively inhibits α-ketoglutaratedependent dioxygenases, including FTO. Consistent with this finding, IDH2 mutant cells exhibit higher levels of m 6 A 52 . Knockout of FTO resulted in elevated m 6 A levels in IDH2 WT but not in IDH2 mutants; the latter observation is consistent with the inhibition of FTO demethylase activity via D-2-hydroxyglutarate-mediated competitive inhibition 52 . These results indicate the need to interpret the consequences of FTO overexpression in AML in the context of mutations that modulate its demethylase activity 52 .
Overexpression of FTO has also been observed in gastric, squamous cell, and breast cancers [53] [54] [55] . FTO overexpression promotes the proliferation and invasiveness of gastric cancer cell lines, and the opposite is true when FTO is depleted in vitro 54 . Increased expression of FTO is associated with advanced tumor stage and poorer survival in gastric cancer, indicating its potential utility as a prognostic marker 54 . Elevated FTO expression in cervical squamous cell carcinoma has been found to enhance chemo-radiotherapy resistance 53 . In breast cancer cell lines, inhibition of FTO reduces PI3K/AKT signaling activity and increases energy metabolism and glycolysis 55 . However, the functional consequences of FTO overexpression on breast cancer cell proliferation and migration remain to be proven experimentally.
ALKBH5
Overexpression of ALKBH5 has been implicated in the maintenance and proliferation of GSCs, thereby conferring oncogenic potential in glioblastoma 22 . Clinically, elevated ALKBH5 levels predict a poorer outcome in patients with glioblastoma. Inhibition of ALKBH5 in GSC cells perturbs brain tumor formation and proliferation in mice, indicating that ALKBH5 overexpression is critical for the development and maintenance of brain tumorigenesis 22 . ALKBH5 targets nascent transcripts encoding the transcription factor FOXM1 and enhances its expression by decreasing m 6 A levels near the 3' UTR. This process is facilitated by a non-coding antisense RNA, FOXM1-AS, that interacts with ALKBH5 and the nascent FOXM1 transcripts 22 . Notably, overexpression of FOXM1 alone is sufficient to reinstate tumorigenesis in mice following ALKBH5 or FOXM1-AS depletion 22 , thereby affirming the role of the ALKBH5-FOXM1-FOXM1-AS axis in the pathogenesis of glioblastoma.
In breast cancer, the hypoxia-triggered HIF1α and HIF2α proteins have been shown to promote ALKBH5 expression 56 . Consequent to increased ALKBH5 expression, a reduction in m 6 A levels promotes the mRNA stability and expression of transcripts encoding the pluripotency factor NANOG 56 . The increase in NANOG expression was shown to result in the accumulation of breast cancer stem cells, which was reversed by depletion of ALKBH5 56 . Overall, ALKBH5 plays a major role in the maintenance of cancer stem cells.
In contrast to the increased expression of ALKBH5 in solid tumors, our own analysis of TCGA data found low levels of ALKBH5 in AML in conjunction with copy number loss 57 . Notably, copy number loss of ALKBH5 is associated with poorer survival and TP53 mutation in AML 57 . While the functional role of ALKBH5 loss in AML remains to be determined, ALKBH5 may act as a tumor suppressor given its lower expression in this type of aggressive leukemia.
Altered m 6 A reader protein expression is involved in cancer YTHDF1/2
The aberrant expression of m 6 A readers in cancers is less well documented. Elevated or depleted levels of m 6 A readers may influence the recognition of m 6 A marks on transcripts, thereby affecting mRNA stability, translation efficiency, and splicing. Several studies have reported the association between overexpression of the YTH family proteins and poorer survival in cancer. For example, YTHDF1 overexpression is associated with a poorer prognosis in HCC and colorectal cancers 58, 59 . The overexpression of YTHDF1 in colorectal cancer has been shown to be transcriptionally driven by the oncogene c-MYC 59 . Notably, c-MYC is translationally enhanced via METTL3 overexpression in other cancers 59 . It would be interesting to investigate whether increased m 6 A abundance on c-MYC-encoding mRNA, consequent to METTL3 overexpression, provides a positive feedback loop to stimulate YTHDF1 expression in cancer.
The overexpression of YTHDF2 has been reported in prostate and pancreatic cancers 60, 61 . In pancreatic cancer, YTHDF2 expression increased in patients at later stages of cancer progression, indicating its potential utility as a prognostic indicator 61 . Inhibition of YTHDF2 expression in prostate and pancreatic cancer cell lines suppresses proliferation and/or colony formation, indicating that YTHDF2 overexpression is oncogenic 60, 61 . Surprisingly, YTHDF2 promotes migration in prostate cancer in vitro, while the opposite has been observed in the case of pancreatic cancer 60, 61 . In pancreatic cancer, YTHDF2 inhibits epithelialmesenchymal transition by suppressing the YES-associated protein (YAP) signaling pathway 61 . Thus, YTHDF2 plays a dual role by coordinating a proliferation and epithelialmesenchymal transition dichotomy in pancreatic cancer 61 . Whether or not the same effect of YTHDF2 overexpression occurs in other cancers remains to be investigated.
IGF2BPs
The recently discovered family of m 6 A reader proteins IGF2BP1-3 has been reported to possess oncogenic potential 29 . These proteins are frequently amplified and expressed at high levels in cancers. In support of their oncogenic role, IGF2BP knockdown in cervical and liver cancer cell lines inhibited proliferation, decreased colony formation, and reduced cell migration and invasion abilities 29 . IGF2BPs act as readers that recognize m 6 A methylation on oncogenes, including MYC, promoting their stability and translation 29 .
Other m 6 A reader proteins
The role of other m 6 A reader proteins in cancer is currently unknown. As YTHDF3 recognizes m 6 A marks on mRNAs to promote translation 62 , it may have a role in promoting the translation of oncogenes, similar to IGF2BP proteins. The aberrant expression of YTHDC1 may alter alternative splicing in cancer by elevating the expression of isoforms with oncogenic potential and/or silencing tumor suppressor genes via production of isoforms subject to nonsensemediated decay 28 . Collectively, there remain many undetermined roles of m 6 A readers in cancer, which require further investigation.
Exploiting the aberrant expression of m 6 A regulators for cancer therapy
Recent studies have indicated that the effectiveness of cancer therapy can be improved by modulating the expression of m 6 A regulatory enzymes 21, 42 . As METTL3 is overexpressed in many cancers, inhibition of this enzyme may be a potential strategy for cancer therapy. METTL3 overexpression has been shown to confer radioresistance in GSCs 35 . Therefore, targeting this enzyme in glioblastoma overexpressing METTL3 in combination with radiotherapy may be an effective therapeutic strategy. Knockdown of METTL3 has been shown to enhance sensitivity to chemo-and radiotherapy in pancreatic cancer cells 63 . However, as reviewed elsewhere, the application of an inhibitor of METTL3 in cancer therapy may be complicated because of its additional functions that are independent of its catalytic activity 64 .
In AML, inducing differentiation in leukemic stem cells has been an effective strategy in the past. Arsenic and alltrans retinoic acid (ATRA) combination therapy induces terminal differentiation of leukemic blasts in acute promyelocytic leukemia (APL), resulting in the cure of this subtype of AML 65 . Other subtypes of AML do not typically respond to ATRA treatment. However, a recent study demonstrated that inhibition of METTL14 promotes terminal differentiation of myeloid cells in vitro 42 . Depletion of METTL14 further sensitizes AML cells, including a non-APL cell line, to ATRA-induced differentiation 42 . It would be interesting to determine whether an inhibitor of METTL14 can be used in combination with ATRA to improve the treatment of AML, particularly those that overexpress METTL14.
Depletion of FTO has also been found to enhance ATRAinduced myeloid differentiation in AML cell lines bearing FTO overexpression 21 . Targeting FTO in combination with ATRA may be a promising approach to treat subsets of AML that overexpress FTO. In addition, FTO has been identified as a target of R-2-hydroxyglutarate (R-2HG), a by-product of mutant IDH1/2 enzymes that is frequently expressed in AML and glioblastoma 66 . R-2HG inhibits the catalytic activity of FTO, thereby increasing m 6 A abundance in mRNAs encoding key oncogenes, including MYC 66 . This leads to the degradation of MYC and inhibition of cancer cell proliferation. Thus, R-2HG possesses a previously unrecognized tumor-suppressor role by reducing FTO expression. The application of IDH1/2-mutant inhibitors alone may not be beneficial to the treatment of cancers bearing mutations of these enzymes 66 . These inhibitors may hinder the favorable effect of R-2HG on suppressing the proliferation and viability of cancer cells. Inhibition of FTO in combination with IDH1/2-mutant inhibitors may be more effective in the treatment of cancers with IDH1/2 mutations, particularly those that also express high levels of FTO 66 .
Small molecule inhibitors against FTO have been developed. Among these, meclofenamic acid has been found to show high selectivity for FTO with minimal effects on ALKBH5 67 . An ethyl ester derivative of meclofenamic acid, MA2, has recently been reported to successfully inhibit glioblastoma stem cell growth in vitro and in vivo 34 . Thus, FTO inhibitors could potentially be repurposed for cancer therapy.
Modulating the levels of m 6 A methylation at specific mRNA targets may ultimately require a full understanding of how m 6 A writers, erasers, and readers interact to promote tumorigenesis. The complex cross-talk between writerserasers-readers functions synergistically to establish an m 6 A threshold that is necessary to maintain the stability of genes controlling cell growth 68 . However, this threshold is also sensitive to oncogenic stimulus. As demonstrated by hypoxia in breast cancer, distortions of the METTL14-ALKBH5-YTHDF3 axis trigger the aberrant expression of specific genes that enhance tumor growth, angiogenesis, and cancer progression 68 . Thus, targeting multiple regulators of m 6 A simultaneously may be necessary to achieve the best outcome.
Conclusions and future perspective
m 6 A RNA modification is central to regulating many biological processes by determining the fate of mRNAs. There is substantial evidence that aberrant regulation of this type of RNA methylation is tumorigenic. Furthermore, dysregulated expression of m 6 A writers, erasers, and readers is widespread in diverse human cancers. Many proteins involved in m 6 A regulation have been only recently characterized, and some of these, including ZC3H13 and CBLL1, have not been studied in the context of cancer. In AML, there have been confounding observations suggesting that the overexpression of both m 6 A writers and erasers can promote tumorigenesis. It is plausible that the overexpression of a particular writer or eraser will modulate m 6 A at different mRNA targets. Additional experiments are required to address the cross-talk among m 6 A writers, erasers, and readers and determine its role in driving AML and other cancers. To date, how m 6 A reader proteins recognize specific mRNA targets also remains a mystery.
In summary, further studies on established and potential regulators of m 6 A and the consequences of their altered expression may provide insights into additional putative roles of m 6 A in cancer biology. Clinically, the aberrant expression of one or more m 6 A regulatory proteins may potentially be used as a diagnostic and prognostic biomarker. Targeting m 6 A regulatory proteins in combination with approved anti-cancer drugs is a new frontier in epigenetic cancer therapeutics.
There are however many hurdles that need to be overcome before feasible therapeutic approaches that target these proteins can be established. The toxicity and sensitivity of various small molecule inhibitors of m 6 A writers and erasers remain to be tested in vivo. Similar to the application of other drugs in cancer cells, ruling out detrimental off-target effects will be crucial. Achieving these objectives is likely to be more challenging if the inhibition of cancer growth and progression requires concomitant modulation of multiple m 6 A writers and erasers. Nevertheless, the burgeoning field of RNA modification has no doubt provided new hope in understanding cancer development and opportunities for novel therapies. Further research will clarify whether a deeper understanding of this field can contribute to an improved management of cancer.
